Perrigo Company plc

Perrigo NYSE: PRGO reported lower third-quarter sales and earnings as cautious retailer inventory decisions and weakness in Europe weighed on results, even as the self-care company gained market share and narrowed its core sales decline.

Perrigo agreed to divest its infant formula business. U.S. e-commerce reached 22% of Perrigo's U.S. volume.

Perrigo Company plc ( PRGO ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Eric Jacobson - Vice President of Global Investor Relations Albert Manzone - Interim President, Interim CEO & Director Eduardo Bezerra - Executive VP & CFO Conference Call Participants Susan Anderson - Canaccord Genuity Corp., Research Division Ethan Brown - JPMorgan Chase & Co, Research Division Presentation Operator Good morning ladies and gentlemen, and welcome to the Perrigo Third Quarter 202…

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.8 per share a year ago.

Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands Infant Formula divestiture expected to simplify portfolio and sharpen focus on higher-return consumer self care categories; strategic review of Oral Care business remains ongoing Updated full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe DUBLIN, Nov. 4, 2026 /PRNewswire/ …

DUBLIN, Oct. 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on December 15, 2026, to shareholders of record on November 27, 2026.

Advances Streamline pillar of Perrigo's Three-S plan through portfolio simplification Furthers Perrigo's evolution into a simpler, more focused consumer self-care company Expected to enhance Perrigo's margin profile and eliminate significant expected future capital expenditures Aligns reported results more closely with the financial profile of Core Perrigo MeridianMade's infant-grade, American manufacturing infrastructure and operating capabilities will support the continued supply of safe, high…

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will hold a conference call beginning at 8:30 a.m.

On October 09, 2026, Perrigo Co PLC (PRGO) shares rose by 3.9%, bringing the current price to $15.06. This movement is notable within the context of its 52-week

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Squarepoint Ops LLC reduced its stake in shares of Perrigo Company plc (NYSE: PRGO) by 95.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,900 shares of the company's stock after selling 443,842 shares during the quarter.

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026.  About Perrigo    Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solu…

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

I present my August top 5 dividend picks: PRGO, MZTI, NEE, TROW, and VICI, all rated Buy or Strong Buy for rising income and appreciation. Each pick trades at a significant discount to fair value (average 21.5%), offering an expected 5-year compound annual total return of ~12.5% and a 5.22% yield. PRGO, MZTI, and VICI stand out for deep undervaluation and robust dividend growth, with VICI offering a projected 15.8% CAGR and strong inflation-linked lease structures.

Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?